The FDA is launching a new effort for post-approval drug safety, called “Safety First,” meant to strengthen its supervision of prescription drugs after approval.     The plan, first reported by the Wall Street Journal and confirmed by FDA spokesman Christopher DiFrancesco, includes the creation of a new database of possible side effects from drugs, and to establish schedules for following up on safety concerns.     The FDA’s plan is an effort to address criticism that the...